Vadadustat:《FDA》安全問題! 美國FDA 拒絕批准Akebia 慢性腎病貧血藥 ...
《FDA》安全問題! 美國FDA 拒絕批准Akebia 慢性腎病貧血藥 ...
![《FDA》安全問題! 美國FDA 拒絕批准Akebia 慢性腎病貧血藥 ...](https://i0.wp.com/api.multiavatar.com/%E3%80%8AFDA%E3%80%8B%E5%AE%89%E5%85%A8%E5%95%8F%E9%A1%8C%21+%E7%BE%8E%E5%9C%8BFDA+%E6%8B%92%E7%B5%95%E6%89%B9%E5%87%86Akebia+%E6%85%A2%E6%80%A7%E8%85%8E%E7%97%85%E8%B2%A7%E8%A1%80%E8%97%A5+....png?apikey=viVnb6N20jclO8)
2022年4月8日—據了解,在該試驗中,雖然使用vadadustat的患者比使用對比藥物的患者出現了更多的血栓栓塞事件,但總體事件發生率是相同的─都是6.6人/100患者年( ...。其他文章還包含有:「Afterhigh」、「Erythropoieticeffectsofvadadustatinpatientswithanemia...」、「FDAProvidesAkebiaTherapeuticsaPathForwardfor...」、「FDA拒絕批准貧血藥物Vadadustat,Akebia大規模裁員」、「VadadustatinPatientswithAnemiaandNon–Di...
查看更多 離開網站![After high](https://i0.wp.com/api.multiavatar.com/After+high-profile+snub%2C+Akebia+plots+vadadustat+....png?apikey=viVnb6N20jclO8)
After high
https://www.fiercepharma.com
Akebia plans to resubmit its application for vadadustat for anemia due to chronic kidney disease in adult patients on dialysis by the end of the ...
![Erythropoietic effects of vadadustat in patients with anemia ...](https://i0.wp.com/api.multiavatar.com/Erythropoietic+effects+of+vadadustat+in+patients+with+anemia+....png?apikey=viVnb6N20jclO8)
Erythropoietic effects of vadadustat in patients with anemia ...
https://pubmed.ncbi.nlm.nih.go
Thus, overall, vadadustat had beneficial effects on three aspects of erythropoiesis in patients with anemia associated with CKD: increased endogenous EPO ...
![FDA Provides Akebia Therapeutics a Path Forward for ...](https://i0.wp.com/api.multiavatar.com/FDA+Provides+Akebia+Therapeutics+a+Path+Forward+for+....png?apikey=viVnb6N20jclO8)
FDA Provides Akebia Therapeutics a Path Forward for ...
https://ir.akebia.com
Vadadustat is approved in Europe for the treatment of symptomatic anemia due to CKD in adult patients on chronic maintenance dialysis. In Japan ...
![FDA 拒絕批准貧血藥物Vadadustat,Akebia 大規模裁員](https://i0.wp.com/api.multiavatar.com/FDA+%E6%8B%92%E7%B5%95%E6%89%B9%E5%87%86%E8%B2%A7%E8%A1%80%E8%97%A5%E7%89%A9Vadadustat%EF%BC%8CAkebia+%E5%A4%A7%E8%A6%8F%E6%A8%A1%E8%A3%81%E5%93%A1.png?apikey=viVnb6N20jclO8)
FDA 拒絕批准貧血藥物Vadadustat,Akebia 大規模裁員
https://geneonline.news
美國食品藥物管理局(FDA)因為安全問題近期拒絕批准美國生物製藥公司Akebia Therapeutics 用於治療慢性腎病引起的貧血藥物Vadadustat,因其增加了血栓
![Vadadustat in Patients with Anemia and Non–Dialysis](https://i0.wp.com/api.multiavatar.com/Vadadustat+in+Patients+with+Anemia+and+Non%E2%80%93Dialysis-+....png?apikey=viVnb6N20jclO8)
Vadadustat in Patients with Anemia and Non–Dialysis
https://www.nejm.org
Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate ...
![Vafseo](https://i0.wp.com/api.multiavatar.com/Vafseo+%7C+European+Medicines+Agency.png?apikey=viVnb6N20jclO8)
Vafseo
https://www.ema.europa.eu
The active substance in Vafseo, vadadustat, acts on an enzyme called hypoxia-inducible factor prolyl hydroxylase (HIF-PH). This stimulates the natural response ...
![Vafseo, INN-vadadustat](https://i0.wp.com/api.multiavatar.com/Vafseo%2C+INN-vadadustat+-+European+Medicines+Agency+%7C.png?apikey=viVnb6N20jclO8)
Vafseo, INN-vadadustat
https://www.ema.europa.eu
Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease. (CKD) in adults on chronic maintenance dialysis. Page 3. 3.
![《FDA》不服慢性腎病貧血藥物Vadadustat藥證申請遭拒! ...](https://i0.wp.com/api.multiavatar.com/%E3%80%8AFDA%E3%80%8B%E4%B8%8D%E6%9C%8D%E6%85%A2%E6%80%A7%E8%85%8E%E7%97%85%E8%B2%A7%E8%A1%80%E8%97%A5%E7%89%A9Vadadustat%E8%97%A5%E8%AD%89%E7%94%B3%E8%AB%8B%E9%81%AD%E6%8B%92%EF%BC%81+....png?apikey=viVnb6N20jclO8)
《FDA》不服慢性腎病貧血藥物Vadadustat藥證申請遭拒! ...
http://www.genetinfo.com
Vadadustat為一種口服缺氧誘導因子脯氨醯羥化酶抑制劑(HIF-PHI),旨在模擬人體對於低水平氧氣的反應,透過抑制HIF-PH可以促進紅血球增生並改善向組織的 ...
![《腎臟病》慢性腎病貧血候選藥物vadadustat 意外落馬](https://i0.wp.com/api.multiavatar.com/%E3%80%8A%E8%85%8E%E8%87%9F%E7%97%85%E3%80%8B%E6%85%A2%E6%80%A7%E8%85%8E%E7%97%85%E8%B2%A7%E8%A1%80%E5%80%99%E9%81%B8%E8%97%A5%E7%89%A9vadadustat+%E6%84%8F%E5%A4%96%E8%90%BD%E9%A6%AC.png?apikey=viVnb6N20jclO8)
《腎臟病》慢性腎病貧血候選藥物vadadustat 意外落馬
http://www.genetinfo.com
今年3 月30 日,美國FDA 以安全性問題,拒絕批准Akebia Therapeutics 原被相當被看好、用於治療慢性腎病貧血的低氧誘導因子脯胺醯羥化酶(HIF-PH) 抑制 ...